Cited by 244Pharmaceutical studies and practicesStatistical Methods in Clinical TrialsPharmacogenetics and Drug Metabolism

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance

Open access

Jamei, Masoud·2016·Current Pharmacology Reports

DOI 10.1007/s40495-016-0059-9PMC PMC4856711

Open this paper in CoChat — free account Open PDF

Abstract

There is a renewed surge of interest in applications of physiologically-based pharmacokinetic (PBPK) models by the pharmaceutical industry and regulatory agencies. Developing PBPK models within a systems pharmacology context allows separation of the parameters pertaining to the animal or human body (the system) from that of the drug and the study design which is essential to develop generic drug-independent models used to extrapolate PK/PD properties in various healthy and patient populations. This has expanded the classical paradigm to a 'predict-learn-confirm-apply' concept. Recently, a number of drug labels are informed by simulation results generated using PBPK models. These cases show that either the simulations are used in lieu of conducting clinical studies or have informed the drug label that otherwise would have been silent in some specific situations. It will not be surprising to see applications of these models in implementing precision dosing at the point of care in the near future.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s40495-016-0059-9

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Fig. 1 A schematic of systems pharmacology paradigm where the systems, drug and trial design data are mechanistically combined and integrated within PBPK models to simulate and predict the drug PK/PD in virtual populations. The Systems and Data are part of the trial setting thence included in the Trial Design boxCC BY · PubMed Central

Fig. 2 The distribution of area of applications of 136 regulatory submissions to FDA (until Oct 2014) where PBPK modelling has been applied, updated by Grillo [10] after [14]CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions
Rodgers, T., & Rowland, M. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20502 · Cited by 949
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Rowland, M., Peck, C., & Tucker, G. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100540 · Cited by 662
Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification
Sager, J. E., Yu, J., Ragueneau, I., & Isoherranen, N. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065920 · Cited by 541
Simulation and prediction of in vivo drug metabolism in human populations from in vitro data
Rostami‐Hodjegan, A., & Tucker, G. T. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2173 · Cited by 533
Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review
Zhao, P., Zhang, L., Grillo, J. A., Liu, Q., Bullock, J. M., Moon, Y. J., Song, P., Brar, S. S., Madabushi, R., Wu, T. C., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.298 · Cited by 524
Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective
Jones, H., Chen, Y., Gibson, C., Heimbach, T., Parrott, N., Peters, S., Snoeys, J., Upreti, V., Zheng, M., & Hall, S. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.37 · Cited by 488
A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of ‘Bottom-Up’ vs ‘Top-Down’ Recognition of Covariates
Jamei, M., Dickinson, G. L., & Rostami‐Hodjegan, A. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.53 · Cited by 377
Self-citation
Physiologically Based Pharmacokinetics Joined with In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology
Rostami-Hodjegan, A. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.65 · Cited by 331
Prediction of Pharmacokinetics Prior to In Vivo Studies. II. Generic Physiologically Based Pharmacokinetic Models of Drug Disposition
Poulin, P., & Theil, F. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10128 · Cited by 303
Application of physiologically based pharmacokinetic (PBPK) modeling to support dose selection: report of an FDA public workshop on PBPK
Wagner, C., Zhao, P., Pan, Y., Hsu, V, Grillo, J., Huang, S., & Sinha, V (2015) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.33 · Cited by 276

Show all 41 references

Sorted by citations

QSAR without borders
Muratov, E. N., Bajorath, J., Sheridan, R. P., Tetko, I. V., Filimonov, D., Poroikov, V., Oprea, T. I., Baskin, I. I., Varnek, A., Roitberg, A., et al. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00098a · Cited by 913
Why Has Model‐Informed Precision Dosing Not Yet Become Common Clinical Reality? Lessons From the Past and a Roadmap for the Future
Darwich, A. S., Ogungbenro, K., Vinks, A. A. T. M. M., Powell, J. R., Reny, J., Marsousi, N., Daali, Y., Fairman, D., Cook, J., Lesko, L. J., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.659 · Cited by 287
Cardiovascular disease models: A game changing paradigm in drug discovery and screening
Savoji, H., Mohammadi, M. H., Rafatian, N., Toroghi, M. K., Wang, E. Y., Zhao, Y., Korolj, A., Ahadian, S., & Radisic, M. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.09.036 · Cited by 223
Physiologically-based pharmacokinetic models for children: Starting to reach maturation?
Verscheijden, L. F. M., Koenderink, J. B., Johnson, T. N., de Wildt, S. N., & Rüssel, F. G. M. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107541 · Cited by 153
An in vitro toolbox to accelerate anti-malarial drug discovery and development
Charman, S. A., Andreu, A., Barker, H., Blundell, S. A., Campbell, A., Campbell, M., Chen, G., Chiu, F. C. K., Crighton, E., Katneni, K., et al. (2020) · Malaria Journal · doi:10.1186/s12936-019-3075-5 · Cited by 154
Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies
Miller, N. A., Reddy, M. B., Heikkinen, A. T., Lukacova, V., & Parrott, N. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00741-9 · Cited by 142
Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective
Lin, W., Chen, Y., Unadkat, J. D., Zhang, X., Wu, D., & Heimbach, T. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03274-2 · Cited by 137
Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine
Hartmanshenn, C., Scherholz, M. L., & Androulakis, I. P. (2016) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-016-9492-y · Cited by 142
Quantitative Proteomics of Clinically Relevant Drug-Metabolizing Enzymes and Drug Transporters and Their Intercorrelations in the Human Small Intestine
Couto, N. A. S., Al‐Majdoub, Z. M., Gibson, S., Davies, P. J., Achour, B., Harwood, M. D., Carlson, G., Barber, J., Rostami‐Hodjegan, A., & Warhurst, G. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.089656 · Cited by 103
Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug
Pathak, S. M., Ruff, A., Kostewicz, E. S., Patel, N. K., Turner, D. B., & Jamei, M. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00406 · Cited by 97
Self-citation
Quantification of Proteins Involved in Drug Metabolism and Disposition in the Human Liver Using Label-Free Global Proteomics
Couto, N. A. S., Al‐Majdoub, Z. M., Achour, B., Wright, P. C., Rostami‐Hodjegan, A., & Barber, J. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00941 · Cited by 94
Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study
Prasad, B., Bhatt, D. K., Johnson, K., Chapa, R., Chu, X., Salphati, L., Xiao, G., Lee, C. G. L., Hop, C. E. C. A., Mathias, A. A., et al. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.080523 · Cited by 91
Bridging the Data Gap From in vitro Toxicity Testing to Chemical Safety Assessment Through Computational Modeling
Zhang, Q., Li, J., Middleton, A., Bhattacharya, S., & Conolly, R. B. (2018) · Frontiers in Public Health · doi:10.3389/fpubh.2018.00261 · Cited by 99
Pharmacokinetic–Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance
Germovsek, E., Barker, C. I. S., Sharland, M., & Standing, J. F. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0659-0 · Cited by 89
Advancing internal exposure and physiologically-based toxicokinetic modeling for 21st-century risk assessments
Hubal, E. A. C., Wetmore, B. A., Wambaugh, J. F., El-Masri, H. A., Sobus, J. R., & Bahadori, T. (2018) · Journal of Exposure Science & Environmental Epidemiology · doi:10.1038/s41370-018-0046-9 · Cited by 82
Usefulness of PBPK Modeling in Incorporation of Clinical Conditions in Personalized Medicine
Marsousi, N., Desmeules, J. A., Rudaz, S. L., & Daali, Y. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.04.035 · Cited by 76
Utilization of Physiologically Based Pharmacokinetic Modeling in Clinical Pharmacology and Therapeutics: an Overview
Perry, C., Davis, G., Conner, T. M., & Zhang, T. (2020) · Current Pharmacology Reports · doi:10.1007/s40495-020-00212-x · Cited by 75
Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations
Ke, A. B., Greupink, R., & Abduljalil, K. (2018) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12274 · Cited by 74
A human population-based organotypic in vitro model for cardiotoxicity screening
Grimm, F. A. (2018) · ALTEX · doi:10.14573/altex.1805301 · Cited by 72
Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation
Polasek, T. M., Tucker, G. T., Sorich, M. J., Wiese, M. D., Mohan, T. S., Rostami‐Hodjegan, A., Korprasertthaworn, P., Perera, V., & Rowland, A. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13480 · Cited by 67
Current Approaches and Techniques in Physiologically Based Pharmacokinetic (PBPK) Modelling of Nanomaterials
Utembe, W., M.A., H. J. C. I., Sanabria, N. M., Doganis, P., & Gulumian, M. (2020) · Nanomaterials · doi:10.3390/nano10071267 · Cited by 69
Impact of Physiologically Based Pharmacokinetic Models on Regulatory Reviews and Product Labels: Frequent Utilization in the Field of Oncology
Yoshida, K. J., Budha, N. R., & Jin, J. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.622 · Cited by 65
Clinical Drug–Drug Interaction Evaluations to Inform Drug Use and Enable Drug Access
Rekić, D., Reynolds, K. S., Zhao, P., Zhang, L., Yoshida, K. J., Sachar, M., Piquette‐Miller, M., Huang, S. M., & Zineh, I. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.04.016 · Cited by 65
An integrated pathway based on in vitro data for the human hazard assessment of nanomaterials
Romeo, D., Salieri, B., Hischier, R., Nowack, B., & Wick, P. (2020) · Environment International · doi:10.1016/j.envint.2020.105505 · Cited by 62
PBPK model reporting template for chemical risk assessment applications
Tan, Y., Chan, M. P. L., Chukwudebe, A. C., Domoradzki, J. Y., Fisher, J. W., Hack, C. E., Hinderliter, P. M., Hirasawa, K., Leonard, J. A., Lumen, A., et al. (2020) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2020.104691 · Cited by 62
New approach methodologies (NAMs) for human-relevant biokinetics predictions
Punt, A. (2020) · ALTEX · doi:10.14573/altex.2003242 · Cited by 61
Reviewing Data Integrated for PBPK Model Development to Predict Metabolic Drug-Drug Interactions: Shifting Perspectives and Emerging Trends
Abouir, K., Samer, C. F., Gloor, Y. S., Desmeules, J. A., & Daali, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.708299 · Cited by 60
Physiologically Based Pharmacokinetic Models Are Effective Support for Pediatric Drug Development
Wang, K., Jiang, K., Wei, X., Li, Y., Wang, T., & Song, Y. (2021) · AAPS PharmSciTech · doi:10.1208/s12249-021-02076-w · Cited by 57
Investigating the state of physiologically based kinetic modelling practices and challenges associated with gaining regulatory acceptance of model applications
Paini, A., Leonard, J. A., Kliment, T., Tan, Y., & Worth, A. P. (2017) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2017.08.019 · Cited by 54
A Scoping Review of the Evidence Behind Cytochrome P450 2D6 Isoenzyme Inhibitor Classifications
Cicali, E. J., Smith, D. M., Duong, B. Q., Kovar, L., Cavallari, L. H., & Johnson, J. A. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1768 · Cited by 53
Prediction of pH-Dependent Drug-Drug Interactions for Basic Drugs Using Physiologically Based Biopharmaceutics Modeling: Industry Case Studies
Mitra, A., Parrott, N. J., Miller, N. A., Lloyd, R. S., Tistaert, C., Heimbach, T., Ji, Y., & Kesisoglou, F. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.11.017 · Cited by 54
The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic Modelling
Badée, J., Fowler, S., de Wildt, S. N., Collier, A., Schmidt, S., & Parrott, N. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0681-2 · Cited by 43
Global Proteomic Analysis of Human Liver Microsomes: Rapid Characterization and Quantification of Hepatic Drug-Metabolizing Enzymes
Achour, B., Feteisi, H. A., Lanucara, F., Rostami‐Hodjegan, A., & Barber, J. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074732 · Cited by 50
Towards best use and regulatory acceptance of generic physiologically based kinetic (PBK) models for in vitro-to-in vivo extrapolation (IVIVE) in chemical risk assessment
Najjar, A., Punt, A., Wambaugh, J. F., Paini, A., Ellison, C. A., Fragki, S., Bianchi, E., Zhang, F., Westerhout, J., Mueller, D., et al. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03356-5 · Cited by 50
Cannabinoids and drug metabolizing enzymes: potential for drug-drug interactions and implications for drug safety and efficacy
Bardhi, K., Coates, S., Watson, C. J. W., & Lazarus, P. J. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2148655 · Cited by 54
Antibody–Drug Conjugates as Cancer Therapeutics: Past, Present, and Future
Vezina, H. E., Cotreau, M. M., Han, T. H., & Gupta, M. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.981 · Cited by 50
Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug–Drug–Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole
Türk, D., Hanke, N., Wolf, S., Frechen, S., Eißing, T., Wendl, T., Schwab, M. G., & Lehr, T. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00777-x · Cited by 48
The Use of Physiologically Based Pharmacokinetic Analyses—in Biopharmaceutics Applications -Regulatory and Industry Perspectives
Anand, O., Pepin, X. J. H., Kolhatkar, V., & Seo, P. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03280-4 · Cited by 50
Quantitative systems pharmacology and the personalized drug–microbiota–diet axis
Thiele, I., Clancy, C. M., Heinken, A., & Fleming, R. M. T. (2017) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2017.06.001 · Cited by 45
What Does it Take to Make Model-Informed Precision Dosing Common Practice? Report from the 1st Asian Symposium on Precision Dosing
Polasek, T. M., Rostami‐Hodjegan, A., Yim, D., Jamei, M., Lee, H., Kimko, H. H. C., Kim, J. K., Phương, N. T. T., Darwich, A. S., & Shin, J. (2019) · The AAPS Journal · doi:10.1208/s12248-018-0286-6 · Cited by 46
Self-citation
Development of a physiologically-based pharmacokinetic pediatric brain model for prediction of cerebrospinal fluid drug concentrations and the influence of meningitis
Verscheijden, L. F. M., Koenderink, J. B., de Wildt, S. N., & Rüssel, F. G. M. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007117 · Cited by 45
Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities
Fowler, S. M., Morcos, P. N., Cleary, Y., Martin‐Facklam, M., Parrott, N. J., Gertz, M., & Yu, L. J. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-017-0082-5 · Cited by 44
A Comprehensive Framework for Physiologically‐Based Pharmacokinetic Modeling in Matlab
Stader, F., Penny, M. A., Siccardi, M., & Marzolini, C. (2019) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12399 · Cited by 45
Utility of physiologically based pharmacokinetic modeling in predicting and characterizing clinical drug interactions
Foti, R. (2024) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001384 · Cited by 43
An updated overview with simple and practical approach for developing in vitro–in vivo correlation
Jacob, S., & Nair, A. B. (2018) · Drug Development Research · doi:10.1002/ddr.21427 · Cited by 42
Application of Physiologically‐Based Pharmacokinetic Modeling to Predict Gastric pH‐Dependent Drug–Drug Interactions for Weak Base Drugs
Dong, Z., Li, J., Wu, F. P., Zhao, P., Lee, S., Zhang, L., Seo, P., & Zhang, L. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12541 · Cited by 42
Prediction of drug‐drug interactions using physiologically‐based pharmacokinetic models of CYP450 modulators included in Simcyp software
Marsousi, N., Desmeules, J. A., Rudaz, S. L., & Daali, Y. (2017) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2107 · Cited by 40
Multi‐phase multi‐layer mechanistic dermal absorption (MPML MechDermA) model to predict local and systemic exposure of drug products applied on skin
Patel, N. K., Clarke, J. F., Salem, F., Abdulla, T., Martins, F. S., Arora, S., Tsakalozou, E., Hodgkinson, A., Arjmandi‐Tash, O., Cristea, S., et al. (2022) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12814 · Cited by 40
Self-citation
Role of pharmacokinetic modeling and simulation in precision dosing of anticancer drugs
Darwich, A. S., Ogungbenro, K., Hatley, O. J. D., & Rostami‐Hodjegan, A. (2017) · Translational Cancer Research · doi:10.21037/tcr.2017.09.14 · Cited by 39
Toward Dynamic Prescribing Information: Codevelopment of Companion Model‐Informed Precision Dosing Tools in Drug Development
Polasek, T. M., Rayner, C. R., Peck, R., Rowland, A., Kimko, H. H. C., & Rostami‐Hodjegan, A. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.638 · Cited by 37
Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products – a PEARRL review
Guimarães, M., Statelova, M., Holm, R., Reppas, C. I., Symillides, M., Vertzoni, M., & Fotaki, N. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12955 · Cited by 37
Towards harmonization of test methods for in vitro hepatic clearance studies
Louisse, J., Alewijn, M., Peijnenburg, A., Cnubben, N. H. P., Heringa, M. B., Coecke, S., & Punt, A. (2019) · Toxicology in Vitro · doi:10.1016/j.tiv.2019.104722 · Cited by 37
Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults
Armani, S., Ting, L. S. L., Sauter, N. P., Darstein, C., Tripathi, A. P., Wang, L., Zhu, B. Y., Gu, H., Chun, D. Y., Einolf, H. J., et al. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0497-0 · Cited by 37
Population-based high-throughput toxicity screen of human iPSC-derived cardiomyocytes and neurons
Huang, C. Y., Nicholson, M. W., Wang, J. Y., Ting, C. Y., Tsai, M. H., Cheng, Y. C., Liu, C. L., Chan, D. Z. H., Lee, Y. C., Hsu, C. C., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110643 · Cited by 36
Systematic Development and Verification of a Physiologically Based Pharmacokinetic Model of Rivaroxaban
Cheong, E. J. Y., Teo, D. W. X., Chua, D. X. Y., & Chan, E. C. Y. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.086918 · Cited by 36
Regional Proteomic Quantification of Clinically Relevant Non-Cytochrome P450 Enzymes along the Human Small Intestine
Zhang, H., Wolford, C., Basit, A., Li, A. P., Fan, P. W., Murray, B. P., Takahashi, R., Khojasteh, S. C., Smith, B. J., Thummel, K. E., et al. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.090738 · Cited by 36
Comparative Hepatic and Intestinal Metabolism and Pharmacodynamics of Statins
Filppula, A. M., Hirvensalo, P., Parviainen, H., Ivaska, V. E., Lönnberg, K. I., Deng, F. Y., Viinamäki, J., Kurkela, M. J., Neuvonen, M., & Niemi, M. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000406 · Cited by 38
Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban—Renal and Hepatic Impairment and Drug‐Drug Interaction Potential
Willmann, S., Coboeken, K., Kapsa, S., Thelen, K., Mundhenke, M., Fischer, K., Hügl, B. J., & Mück, W. M. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1784 · Cited by 39
Phenotypic chemical biology for predicting safety and efficacy
Berg, E. L. (2017) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2017.01.001 · Cited by 33
Physiologically Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) as a Victim and Perpetrator of Drug-Drug Interactions
Einolf, H. J., Lin, W., Won, C. S., Wang, L., Gu, H., Chun, D. Y., He, H., & Mangold, J. B. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.076851 · Cited by 34
Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines
Paglialunga, S., Offman, E., Ichhpurani, N., Marbury, T., & Morimoto, B. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1274651 · Cited by 27
Quantitative mass spectrometry-based proteomics in the era of model-informed drug development: Applications in translational pharmacology and recommendations for best practice
El‐Khateeb, E., Vasilogianni, A., Alrubia, S., Al‐Majdoub, Z. M., Couto, N. A. S., Howard, M., Barber, J., Rostami‐Hodjegan, A., & Achour, B. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107397 · Cited by 32
A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug–Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients
Einolf, H. J., Zhou, J., Won, C. S., Wang, L., & Rebello, S. S. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.073585 · Cited by 32
Sound understanding of environmental, health and safety, clinical, and market aspects is imperative to clinical translation of nanomedicines
Rösslein, M., Liptrott, N. J., Owen, A., Boisseau, P., Wick, P., & Herrmann, I. K. (2017) · Nanotoxicology · doi:10.1080/17435390.2017.1279361 · Cited by 32
Incorporation of the Time-Varying Postprandial Increase in Splanchnic Blood Flow into a PBPK Model to Predict the Effect of Food on the Pharmacokinetics of Orally Administered High-Extraction Drugs
Rose, R. H., Turner, D. B., Neuhoff, S., & Jamei, M. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0099-z · Cited by 31
Self-citation
Real Patient and its Virtual Twin: Application of Quantitative Systems Toxicology Modelling in the Cardiac Safety Assessment of Citalopram
Patel, N., Wiśniowska, B., Jamei, M., & Polak, S. (2017) · AAPS Journal · doi:10.1208/s12248-017-0155-8 · Cited by 35
Self-citation
Model‐Based Assessments of CYP‐Mediated Drug–Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development
Cleary, Y., Gertz, M., Morcos, P. N., Yu, L. J., Youdim, K. A., Phipps, A., Fowler, S. M., & Parrott, N. J. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.956 · Cited by 31
Model‐Informed Pediatric Dose Selection for Dapagliflozin by Incorporating Developmental Changes
Jo, H., Reddy, V. P., PARKINSON, J. R., Boulton, D. W., & Tang, W. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12577 · Cited by 31
Proteomic Quantification of Changes in Abundance of Drug-Metabolizing Enzymes and Drug Transporters in Human Liver Cirrhosis: Different Methods, Similar Outcomes
El‐Khateeb, E., Al‐Majdoub, Z. M., Rostami‐Hodjegan, A., Barber, J., & Achour, B. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000484 · Cited by 29
Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of In Vivo Clinical Studies: Current Status, Challenges, and Opportunities
Loisios-Konstantinidis, I., & Dressman, J. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00903 · Cited by 30
IntegratingIn Vitro, Modeling, andIn VivoApproaches to Investigate Warfarin Bioequivalence
Zhang, X., Wen, H. Y., Fan, J., Vince, B. D., Li, T., Gao, W., Kinjo, M., Brown, J., Sun, W., Jiang, W., et al. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12198 · Cited by 30
Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John’s Wort
Adiwidjaja, J., Boddy, A. V., & McLachlan, A. J. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00736-6 · Cited by 30
Investigating Oral Absorption of Carbamazepine in Pediatric Populations
Kohlmann, P., Stillhart, C., Kuentz, M., & Parrott, N. J. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0149-6 · Cited by 30
Global Sensitivity Analysis of the Rodgers and Rowland Model for Prediction of Tissue: Plasma Partitioning Coefficients: Assessment of the Key Physiological and Physicochemical Factors That Determine Small-Molecule Tissue Distribution
Yau, E., Olivares‐Morales, A., Gertz, M., Parrott, N. J., Darwich, A. S., Aarons, L. J., & Ogungbenro, K. (2020) · The AAPS Journal · doi:10.1208/s12248-020-0418-7 · Cited by 28
Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
Morcos, P. N., Cleary, Y., Sturm, C., Guerini, E., Abt, M., Donzelli, M., Vazvaei, F., Balas, B. I., Parrott, N. J., & Yu, L. J. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1286 · Cited by 28
Ontogeny of Drug-Metabolizing Enzymes
Thakur, A., Parvez, M. M., Leeder, J. S., & Prasad, B. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1554-6_18 · Cited by 28
Translatability and transferability of in silico models: Context of use switching to predict the effects of environmental chemicals on the immune system
Pappalardo, F., Russo, G. L., Corsini, E., Paini, A., & Worth, A. P. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.03.024 · Cited by 26
A Review on AI-Based Data-Driven Models for Optimization of Nanocarriers as Drug Delivery Systems
Kantesaria, R., & Panda, H. S. (2026) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c01998 · Cited by 27
Population PBPK modeling using parametric and nonparametric methods of the Simcyp Simulator, and Bayesian samplers
Wedagedera, J. R., Onasanwo, A., Chirumamilla, S. K., Momiji, H., Leary, R. H., Dunlavey, M., Matthews, R., Abduljalil, K., Jamei, M., & Bois, F. Y. (2022) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12787 · Cited by 26
Self-citation
Predicting topical drug clearance from the skin
Tabosa, M. A. M., Hoppel, M., Bunge, A. L., Guy, R. H., & Delgado-Charro, M. B. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00864-8 · Cited by 26
Tackling pharmacological response heterogeneity by PBPK modeling to advance precision medicine productivity of nanotechnology and genomics therapeutics
Vizirianakis, I. S., Miliotou, Α. N., Mystridis, G. A., Andriotis, E. G., Andreadis, I. I., Papadopoulou, L. C., & Fatouros, D. G. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1605828 · Cited by 25
Physiologically Based Pharmacokinetic Modeling and Allometric Scaling in Pediatric Drug Development: Where Do We Draw the Line?
Johnson, T. N., & Ke, A. B. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1834 · Cited by 25
A 20-Year Research Overview: Quantitative Prediction of Hepatic Clearance Using the In Vitro-In Vivo Extrapolation Approach Based on Physiologically Based Pharmacokinetic Modeling and Extended Clearance Concept
Sugiyama, Y., & Aoki, Y. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001344 · Cited by 25
Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications
Stader, F., Kinvig, H., Battegay, M., Khoo, S., Owen, A., Siccardi, M., & Marzolini, C. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00717-18 · Cited by 25
Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation
Stader, F., Courlet, P., Kinvig, H., Battegay, M., Decosterd, L. A., Penny, M. A., Siccardi, M., & Marzolini, C. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14402 · Cited by 24
Scientific considerations to move towards biowaiver for biopharmaceutical classification system class III drugs: How modeling and simulation can help
Wu, F. P., Cristofoletti, R., Zhao, L. Y., & Rostami‐Hodjegan, A. (2021) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2274 · Cited by 25
Physiologically‐based pharmacokinetics of ziprasidone in pregnant women
Biesdorf, C., Martins, F. S., Sy, S. K. B., & Diniz, A. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13872 · Cited by 24
Nursing Personnel in the Era of Personalized Healthcare in Clinical Practice
Spanakis, M., Patelarou, A. E., & Patelarou, E. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030056 · Cited by 23
Implications of intercorrelation between hepatic CYP3A4‐CYP2C8 enzymes for the evaluation of drug–drug interactions: a case study with repaglinide
Doki, K., Darwich, A. S., Achour, B., Tornio, A., Backman, J. T., & Rostami‐Hodjegan, A. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13533 · Cited by 23
Sampling Site Has a Critical Impact on Physiologically Based Pharmacokinetic Modeling
Huang, W., & Isoherranen, N. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.262154 · Cited by 23
Can PBPK Modeling Streamline Food Effect Assessments?
Kesisoglou, F. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1678 · Cited by 22
Formation of PFAAs in fish through biotransformation: A PBPK approach
Mittal, V. K., & Ng, C. A. (2018) · Chemosphere · doi:10.1016/j.chemosphere.2018.03.064 · Cited by 23
The development of a population physiologically based pharmacokinetic model for mycophenolic mofetil and mycophenolic acid in humans using data from plasma, saliva, and kidney tissue
Alsmadi, M. M., Alfarah, M. Q., Albderat, J., Alsalaita, G., Almardini, R. I., Hamadi, S., Al‐Ghazawi, A., Abu‐Duhair, O., & Idkaidek, N. (2019) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2206 · Cited by 22
Development of a paediatric physiologically based pharmacokinetic model to assess the impact of drug-drug interactions in tuberculosis co-infected malaria subjects: A case study with artemether-lumefantrine and the CYP3A4-inducer rifampicin
Olafuyi, O., Coleman, M. D., & Badhan, R. K. S. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.05.043 · Cited by 22
Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics
Lenoir, C., Niederer, A., Rollason, V., Desmeules, J. A., Daali, Y., & Samer, C. F. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12730 · Cited by 20
Assessing Potential Drug–Drug Interactions Between Dabigatran Etexilate and a P‐Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling
Doki, K., Neuhoff, S., Rostami‐Hodjegan, A., & Homma, M. (2019) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12382 · Cited by 21
Development and verification of an endogenous PBPK model to inform hydrocortisone replacement dosing in children and adults with cortisol deficiency
Bonner, J. J., Burt, H. J., Johnson, T. N., Whitaker, M. J., Porter, J. B., & Ross, R. J. M. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105913 · Cited by 21
Computational Fluid-Particle Dynamics Modeling for Unconventional Inhaled Aerosols in Human Respiratory Systems
Feng, Y., Xu, Z., & Haghnegahdar, A. (2016) · InTech eBooks · doi:10.5772/65361 · Cited by 21
Does the choice of applied physiologically‐based pharmacokinetics platform matter? A case study on simvastatin disposition and drug–drug interaction
Prieto Garcia, L., Lundahl, A., Ahlström, C., Vildhede, A., Lennernäs, H., & Sjögren, E. (2022) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12837 · Cited by 21
Multi-scale models of whole cells: progress and challenges
Georgouli, K., Yeom, J.-S., Blake, R. C., & Navid, A. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1260507 · Cited by 20

Authors: Jamei, M.
Affiliations: Simcyp (United Kingdom) (GB)
Corresponding author: Jamei, Masoud
ORCID: Jamei, Masoud
Venue: Current Pharmacology Reports
Publisher: Springer Science and Business Media LLC
Published: 2016-04-14
Volume: 2
Issue: 3
Pages: 161-169
ISSN: 2198-641X (ISSN-L)
DOI: 10.1007/s40495-016-0059-9
PMC: PMC4856711
OpenAlex: W2341647963
Cited by: 244
References: 41
Citations by year: 2026: 10 · 2025: 21 · 2024: 17 · 2023: 29 · 2022: 20 · 2021: 25 · 2020: 31 · 2019: 24 · 2018: 24 · 2017: 37 · 2016: 6
FWCI: 4.70
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0 (unspecified)
Locations: Current Pharmacology Reports (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Funders: Simcyp Limited (A Certara Company)
Topics: Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords: physiologically based pharmacokinetic modeling, regulatory acceptance, systems pharmacology, precision dosing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks